Compazine and Carbohydrate antigen 125 increased - a phase IV clinical study of FDA data

Summary:

Carbohydrate antigen 125 increased is reported as a side effect among people who take Compazine (prochlorperazine maleate), especially for people who are female, 60+ old, also take Zejula, and have Ovarian cancer.

The phase IV clinical study analyzes which people have Carbohydrate antigen 125 increased when taking Compazine. It is created by eHealthMe based on reports of 13,599 people who have side effects when taking Compazine from the FDA, and is updated regularly.

What is Compazine?

Compazine has active ingredients of prochlorperazine maleate. It is often used in indigestion. eHealthMe is studying from 13,646 Compazine users. Check the latest studies of Compazine.

What is Carbohydrate antigen 125 increased?

Carbohydrate antigen 125 increased is found to be associated with 270 drugs and 250 conditions by eHealthMe. Check the latest studies of Carbohydrate antigen 125 increased.

On Jul, 19, 2026

13,599 people reported to have side effects when taking Compazine.
Among them, 81 people (0.6%) have Carbohydrate antigen 125 increased.

Could Compazine cause Carbohydrate antigen 125 increased?

Among these 81 people:

What is the gender of people who have Carbohydrate antigen 125 increased when taking Compazine? *

female: 100 %
male: 0.0 %

What is the age of people who have Carbohydrate antigen 125 increased when taking Compazine? *

What are other drugs people take besides Compazine? *

What are other side effects people have besides Carbohydrate antigen 125 increased? *

Fatigue (feeling of tiredness): 44 people, 54.32%
Constipation: 42 people, 51.85%
Thrombocytopenia (decrease of platelets in blood): 36 people, 44.44%
High Blood Pressure: 31 people, 38.27%
Insomnia (sleeplessness): 28 people, 34.57%
Haemoglobin Decreased: 25 people, 30.86%
White Blood Cell Count Decreased: 24 people, 29.63%
Red Blood Cell Count Decreased: 23 people, 28.40%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 20 people, 24.69%
Headache (pain in head): 20 people, 24.69%

What are the existing conditions these people have? *

Ovarian Cancer (cancer of ovary): 66 people, 81.48%
Pain: 9 people, 11.11%
Constipation: 9 people, 11.11%
Fallopian Tube Cancer (cancer of fallopian tube): 5 people, 6.17%
Malignant Peritoneal Neoplasm (cancer tumour of peritoneum): 5 people, 6.17%
Ovarian Cancer Stage Iv: 3 people, 3.70%
Urinary Tract Infection: 3 people, 3.70%
Sleep Disorder: 3 people, 3.70%
High Blood Pressure: 3 people, 3.70%
Asthma: 2 people, 2.47%

* Approximation only. Some reports may have incomplete information.

Do you take Compazine and have Carbohydrate antigen 125 increased?

- Check whether Carbohydrate antigen 125 increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Compazine:

Compazine (13,646 reports)

Browse all side effects of Compazine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Carbohydrate antigen 125 increased:

Carbohydrate antigen 125 increased (270 drugs)

Browse all the conditions that are associated with Carbohydrate antigen 125 increased:

Carbohydrate antigen 125 increased (250 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on prochlorperazine maleate (the active ingredients of Compazine) and Compazine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.